November 4, 2025 – Talk Bio

Novo Nordisk Ups Metsera Bid to $10 Billion to Top Pfizer’s Offer

2 hours ago talkbio0Tagged Acquisition, contingent value right, Diabetes, M&A, Metsera, Novo Nordisk, Obesity, Pfizer

Novo Nordisk; Metsera; Pfizer; M&A; biotech acquisition; contingent value right; obesity drugs; diabetes treatments

Blackstone Pays Merck $700M to Fund Development of Antibody-Drug Conjugate

2 hours ago talkbio0Tagged Antibody-Drug Conjugates, Blackstone, cancer drug development, funding agreement, Merck, Neoplasms, royalties, sacituzumab tirumotecan

Blackstone; Merck; sacituzumab tirumotecan; antibody-drug conjugate; cancer drug development; funding agreement; oncology; royalties

Sarepta’s Duchenne Muscular Dystrophy Drugs Fail Confirmatory Trial, Company Pursues Full FDA Approval Regardless

2 hours ago talkbio0Tagged Accelerated, AMONDYS, Approved, Clinical trial failure, Confirmatory Trial, ELEVIDYS, Muscular Dystrophy, Duchenne, Statistical Significance, United States Food and Drug Administration

Sarepta Therapeutics; Duchenne muscular dystrophy; confirmatory trial; AMONDYS 45; VYONDYS 53; Elevidys; FDA approval; clinical trial failure; accelerated approval; statistical significance

UCB Wins First FDA Approval for Ultra-Rare Mitochondrial Disease: Kygevvi for Thymidine Kinase 2 Deficiency (TK2d)

6 hours ago talkbio0Tagged Approved, Breakthrough Therapy, doxecitine, doxribtimine, Drugs, Orphan, Infrequent, Kygevvi, Mitochondrial Diseases, Pediatric Disorder, Priority Review, Thymidine kinase 2 deficiency, TK2d, UCB, United States Food and Drug Administration

UCB; FDA approval; Kygevvi; mitochondrial disease; Thymidine Kinase 2 deficiency; TK2d; doxecitine; doxribtimine; rare diseases; Orphan Drug; Breakthrough Therapy; Priority Review; Rare Pediatric Disease

TScan Cuts Workforce by 30% While Iovance Advances Amtagvi Program Amid Layoffs

10 hours ago talkbio0Tagged Amtagvi, Cell Therapy, Iovance Biotherapeutics, layoffs, Lymphocytes, Tumor-Infiltrating, Malignant neoplasm of lung, melanoma, strategic restructuring, TScan Therapeutics

TScan Therapeutics; layoffs; Iovance Biotherapeutics; Amtagvi; tumor-infiltrating lymphocyte (TIL) therapy; melanoma; lung cancer; strategic restructuring; biotech layoffs; cell therapy

Metsera Calls Pfizer’s Threats ‘Nonsense’ as Rift Between Companies Widens

10 hours ago talkbio0Tagged Chancery, Delaware Court, drug acquisition, Litigation, Merger, Metsera, Novo Nordisk, Obesity, Pfizer, regulatory approval

Metsera; Pfizer; Novo Nordisk; merger dispute; litigation; obesity drug acquisition; regulatory approval; Delaware Court of Chancery

Eli Lilly to Invest $3 Billion in New European Factory for Weight-Loss Pill Orforglipron

10 hours ago talkbio0Tagged advanced manufacturing, eli lilly, European market, global supply chain, Leiden Bio Science Park, Manufacturing Facilities, Netherlands, obesity pill, orforglipron, Product containing glucagon-like peptide 1 receptor agonist (product)

Eli Lilly; Orforglipron; obesity pill; Leiden Bio Science Park; Netherlands; GLP-1 receptor agonist; manufacturing facility; European market; advanced manufacturing; global supply chain

Recent News: Live at 11 a.m. ET – M&A, FDA, MFN and Collaboration with FT

10 hours ago talkbio0Tagged Acquisitions, Drug Approval, Economics, Financial Times, Live - Specimen Condition, M&A, mergers, MFN, News [Publication Type], United States Food and Drug Administration

M&A; FDA; MFN; Financial Times; mergers and acquisitions; drug approval; economics; live news

M42 and Oracle Join Forces to Advance Healthy Longevity and Disease Prevention

13 hours ago talkbio0Tagged disease prevention, electronic health record - ActClassContainer, Emirati Genome Program, healthy longevity, Oracle Health, personalized healthcare, Pharmacogenomics, Precision Medicine, UAE

M42; Oracle Health; healthy longevity; disease prevention; precision medicine; Emirati Genome Program; pharmacogenomics; electronic health record (EHR); personalized healthcare; UAE

Life Biosciences Appoints Industry Veteran David Guyer, M.D. to Board of Directors

23 hours ago talkbio0Tagged Aging, Biotechnology, board of directors, cellular rejuvenation, David Guyer, Drug Development, epigenetic reprogramming, ER-100, Life Biosciences

Life Biosciences; David Guyer; Board of Directors; biotechnology; cellular rejuvenation; epigenetic reprogramming; ER-100; aging; drug development